C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel

Objective/Background: Chimeric antigen receptor (CAR) T-cell is an effective therapy in relapsed/refractory large B-cell lymphomas that, due to its unique toxicities, often requires escalation of care to the intensive care unit (ICU) setting. C-reactive protein (CRP) and ferritin are serum inflammat...

Full description

Bibliographic Details
Main Authors: Megan Melody, Zaid Abdel Rahman, Hollie Saunders, Paula Lengerke Diaz, Nicole Gannon, Allison Rosenthal, Ernesto Ayala, Han W. Tun, Hemant Murthy, Vivek Roy, James Foran, Januario E. Castro, Pramod Guru, Mohamed A. Kharfan-Dabaja
Format: Article
Language:English
Published: Elsevier 2021-06-01
Series:Hematology/Oncology and Stem Cell Therapy
Subjects:
CRP
Online Access:http://www.sciencedirect.com/science/article/pii/S1658387620301515
id doaj-844ab7651846403fbcc18b946b082f45
record_format Article
spelling doaj-844ab7651846403fbcc18b946b082f452021-05-22T04:36:21ZengElsevierHematology/Oncology and Stem Cell Therapy1658-38762021-06-01142141146C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucelMegan Melody0Zaid Abdel Rahman1Hollie Saunders2Paula Lengerke Diaz3Nicole Gannon4Allison Rosenthal5Ernesto Ayala6Han W. Tun7Hemant Murthy8Vivek Roy9James Foran10Januario E. Castro11Pramod Guru12Mohamed A. Kharfan-Dabaja13Department of Internal Medicine, Mayo Clinic, Jacksonville, FL, USADivision of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USADepartment of Internal Medicine, Mayo Clinic, Jacksonville, FL, USADivision of Hematology-Oncology and Blood and Marrow Transplantation, Mayo Clinic, Phoenix, AZ, USADivision of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USADivision of Hematology-Oncology and Blood and Marrow Transplantation, Mayo Clinic, Phoenix, AZ, USADivision of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USADivision of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USADivision of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USADivision of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USADivision of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USADivision of Hematology-Oncology and Blood and Marrow Transplantation, Mayo Clinic, Phoenix, AZ, USADepartment of Critical Care Medicine, Mayo Clinic, Jacksonville, FL, USADivision of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Program, Mayo Clinic, Jacksonville, FL, USA; Corresponding author at: Mayo Clinic, 4500 San Pablo Rd S, Mangurian Building, 3rd Floor, Jacksonville, FL 32224, USA.Objective/Background: Chimeric antigen receptor (CAR) T-cell is an effective therapy in relapsed/refractory large B-cell lymphomas that, due to its unique toxicities, often requires escalation of care to the intensive care unit (ICU) setting. C-reactive protein (CRP) and ferritin are serum inflammatory markers associated with onset and persistence of CAR T-cell-related toxicity. Methods: We retrospectively analyzed 34 patients treated with axicabtagene ciloleucel (axi-cel) who were divided into two groups: patients requiring admission to the ICU during initial hospitalization (n = 13, 38%) and those who did not (n = 21, 62%). Primary objective was to examine possible relationships between serum ferritin and/or CRP levels with the need for, and length of, ICU stay between these groups. Results: All 13 patients admitted to the ICU developed cytokine release syndrome (CRS) and 11 of them also developed neurotoxicity (NT). Of the 21 patients in the non-ICU group, 18 developed CRS and 5 patients developed NT. Grade of CRS and NT were higher in ICU versus non-ICU patients (p = .03 and .001, respectively). There was no correlation between CRP levels at time of ICU admission and length of ICU stay (correlation of 0.41, p = .17). Yet, there was an association between serum ferritin levels and length of ICU stay (R2 = 0.73) which did not reach statistical significance (correlation of 0.21, p = .49). Conclusion: Notwithstanding the limitations of the small sample size, our study suggests that an elevated ferritin level at the time of escalation of medical care may be possibly indicative of anticipated prolonged ICU hospitalization in patients treated with axi-cel. A large multicenter study is certainly needed to confirm this observation.http://www.sciencedirect.com/science/article/pii/S1658387620301515Axicabtagene ciloleucelCAR T cellCRPDLBCLFerritin
collection DOAJ
language English
format Article
sources DOAJ
author Megan Melody
Zaid Abdel Rahman
Hollie Saunders
Paula Lengerke Diaz
Nicole Gannon
Allison Rosenthal
Ernesto Ayala
Han W. Tun
Hemant Murthy
Vivek Roy
James Foran
Januario E. Castro
Pramod Guru
Mohamed A. Kharfan-Dabaja
spellingShingle Megan Melody
Zaid Abdel Rahman
Hollie Saunders
Paula Lengerke Diaz
Nicole Gannon
Allison Rosenthal
Ernesto Ayala
Han W. Tun
Hemant Murthy
Vivek Roy
James Foran
Januario E. Castro
Pramod Guru
Mohamed A. Kharfan-Dabaja
C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel
Hematology/Oncology and Stem Cell Therapy
Axicabtagene ciloleucel
CAR T cell
CRP
DLBCL
Ferritin
author_facet Megan Melody
Zaid Abdel Rahman
Hollie Saunders
Paula Lengerke Diaz
Nicole Gannon
Allison Rosenthal
Ernesto Ayala
Han W. Tun
Hemant Murthy
Vivek Roy
James Foran
Januario E. Castro
Pramod Guru
Mohamed A. Kharfan-Dabaja
author_sort Megan Melody
title C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel
title_short C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel
title_full C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel
title_fullStr C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel
title_full_unstemmed C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel
title_sort c-reactive protein and ferritin levels and length of intensive care unit stay in patients with b-cell lymphomas treated with axicabtagene ciloleucel
publisher Elsevier
series Hematology/Oncology and Stem Cell Therapy
issn 1658-3876
publishDate 2021-06-01
description Objective/Background: Chimeric antigen receptor (CAR) T-cell is an effective therapy in relapsed/refractory large B-cell lymphomas that, due to its unique toxicities, often requires escalation of care to the intensive care unit (ICU) setting. C-reactive protein (CRP) and ferritin are serum inflammatory markers associated with onset and persistence of CAR T-cell-related toxicity. Methods: We retrospectively analyzed 34 patients treated with axicabtagene ciloleucel (axi-cel) who were divided into two groups: patients requiring admission to the ICU during initial hospitalization (n = 13, 38%) and those who did not (n = 21, 62%). Primary objective was to examine possible relationships between serum ferritin and/or CRP levels with the need for, and length of, ICU stay between these groups. Results: All 13 patients admitted to the ICU developed cytokine release syndrome (CRS) and 11 of them also developed neurotoxicity (NT). Of the 21 patients in the non-ICU group, 18 developed CRS and 5 patients developed NT. Grade of CRS and NT were higher in ICU versus non-ICU patients (p = .03 and .001, respectively). There was no correlation between CRP levels at time of ICU admission and length of ICU stay (correlation of 0.41, p = .17). Yet, there was an association between serum ferritin levels and length of ICU stay (R2 = 0.73) which did not reach statistical significance (correlation of 0.21, p = .49). Conclusion: Notwithstanding the limitations of the small sample size, our study suggests that an elevated ferritin level at the time of escalation of medical care may be possibly indicative of anticipated prolonged ICU hospitalization in patients treated with axi-cel. A large multicenter study is certainly needed to confirm this observation.
topic Axicabtagene ciloleucel
CAR T cell
CRP
DLBCL
Ferritin
url http://www.sciencedirect.com/science/article/pii/S1658387620301515
work_keys_str_mv AT meganmelody creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel
AT zaidabdelrahman creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel
AT holliesaunders creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel
AT paulalengerkediaz creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel
AT nicolegannon creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel
AT allisonrosenthal creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel
AT ernestoayala creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel
AT hanwtun creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel
AT hemantmurthy creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel
AT vivekroy creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel
AT jamesforan creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel
AT januarioecastro creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel
AT pramodguru creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel
AT mohamedakharfandabaja creactiveproteinandferritinlevelsandlengthofintensivecareunitstayinpatientswithbcelllymphomastreatedwithaxicabtageneciloleucel
_version_ 1721430892552912896